Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ACT-20 in Patients With Severe COVID-19 Pneumonia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04398303
Recruitment Status : Not yet recruiting
First Posted : May 21, 2020
Last Update Posted : May 21, 2020
Sponsor:
Information provided by (Responsible Party):
Aspire Health Science

Brief Summary:
The primary objective of this study is determine the safety and efficacy of ACT-20-MSC (allogenic human umbilical derived mesenchymal stem cells) and ACT-20-CM (allogenic human umbilical derived mesenchymal stem cells in conditioned media) in patients with moderate to severe COVID-19 pneumonia.

Condition or disease Intervention/treatment Phase
COVID-19 Pneumonia Biological: ACT-20-MSC Biological: ACT-20-CM Biological: Placebo Phase 1 Phase 2

Detailed Description:

This study will assess the safety and efficacy of ACT-20-MSC and ACT-20-CM administered intravenously to subjects with moderate to severe COVID-19 related pneumonia in two parts.

Part 1 is an open-label study of 10 subjects, 5 with moderate COVID-19 pneumonia and 5 with severe COVID-19 pneumonia. Of these 10 subjects, 5 will receive ACT-20-CM and 5 will receive ACT-20-MSC resuspended in ACT-20-CM.

Part 2 is a randomized, blinded, placebo-controlled study of 60 patients, 30 with moderate COVID-19 pneumonia and 30 with severe COVID-19 pneumonia. Randomization will be 1:1:1 ACT-20-MSC in ACT-20-CM, ACT-20-CM or placebo. The placebo is MEM-α, a widely used sterile culture media that contains non-essential amino acids, nucleosides, vitamins, glucose, sodium pyruvate and lipoic acid.

Subjects treated at each investigative site will provide written informed consent prior to the conduct of any study-related procedures. Thereafter, they will be screened and those meeting the inclusion/exclusion criteria will be enrolled into the trial and undergo all the study procedures including the intravenous administration of the investigational medical product (IMP = ACT-20-MSC in ACT-20-CM or ACT-20-CM) or placebo. The IMP will be administered in addition to any standard of care treatment the subject is receiving.

Subjects will be assessed daily while in hospital. Following discharge from hospital, subjects will be following for an additional three month period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 Pneumonia
Estimated Study Start Date : May 2020
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arm Intervention/treatment
Experimental: ACT-20-MSC in ACT-20-CM
Conventional treatment plus ACT-20-MSC in ACT-20-CM administered intravenously
Biological: ACT-20-MSC
1 million cells / kg body weight in 100 ml in conditioned media

Experimental: ACT-20-CM
Conventional treatment plus ACT-20-CM administered intravenously
Biological: ACT-20-CM
100 ml of conditioned media only

Placebo Comparator: Placebo
Conventional treatment plus placebo (MEM-α) administered intravenously
Biological: Placebo
100 ml of MEM-α




Primary Outcome Measures :
  1. Mortality at day 30 [ Time Frame: 30 days post treatment ]

Secondary Outcome Measures :
  1. Ventilated Subjects - Ventilator Free Days [ Time Frame: 28 days post treatment ]
    Number of ventilator-free days

  2. Ventilated Subjects - Improvement in Ventilator Settings [ Time Frame: 28 days post treatment, or until off of ventilator ]
    Improvement in ventilator settings: Minute ventilation, PEEP, FiO2

  3. High-Flow O2 Support Subjects - Step-Down O2 Therapy [ Time Frame: 30 days post treatment, or until off of high-flow O2 support ]
    Days of step-down O2 therapy as evidenced by: improvement in required volume, change to nasal cannula or face mask delivery or improvement in required concentration.

  4. High Flow O2 Support Subjects - Respiration Rate [ Time Frame: 30 days post treatment, or until off of high-flow O2 support ]
    Respiration Rate < 30 for > 24 hours.

  5. Both Ventilated and High-Flow O2 Support Subjects - ICU-Free Days [ Time Frame: 30 days post treatment, or until off of ventilator or high-flow O2 support ]
    Number of ICU-free days

  6. Both Ventilated and High-Flow O2 Support Subjects - Pulmonary Function Improvement [ Time Frame: 30 days post treatment, or until off of ventilator or high-flow O2 support ]
    Improvement in pulmonary function as evidenced by A-A oxygen gradient, O2 saturation

  7. Both Ventilated and High-Flow O2 Support Subjects - Increased Berlin Score [ Time Frame: 30 days post treatment, or until off of ventilator or high-flow O2 support ]
    Increased Berlin Criteria score > 24 hours



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients age 18 to 85, inclusive
  2. Confirmed positive test for COVID-19 by standard reverse transcriptase polymerase chain reaction (RT-PCR) assay or equivalent
  3. On mechanical ventilation (n=35), or high-flow O2 support (n=35) and:

    1. Disease severity level of "moderate" (PaO2/FiO2 of 100-200) (n=35), or "severe" (PaO2/FiO2 < 100) (n=35) as established using the Berlin Criteria for ARDS (Barbas, Isola & Caser, 2014; Baron & Levy, 2016).
    2. Positive end-expiratory airway pressure (PEEP) ≥ 5 cmH2O
    3. Oxygen saturation ≤ 93%
  4. Non-cardiogenic bilateral pulmonary edema on frontal chest radiograph that cannot be explained by effusion, collapsed lung or lung nodule
  5. Able to understand and provide voluntary informed consent

Exclusion Criteria:

  1. Unable to understand and provide voluntary informed consent
  2. Current infection with HIV-1, HIV-2, Hepatitis B, Hepatitis C or HTLV
  3. History of malignancy, other than non-melanoma skin cancer or non-metastatic prostate cancer
  4. Currently receiving extracorporeal life support or high-frequency oscillatory ventilation
  5. Weight > 150 kg
  6. Current severe chronic respiratory disease, as demonstrated by:

    1. PaCO2 > 50 mm Hg, or
    2. history of use of home oxygen
  7. Major trauma within the past 7 days
  8. Lung transplant recipient
  9. WHO Class III or IV pulmonary hypertension
  10. Documented deep vein thrombosis or pulmonary embolism within the past 3 months
  11. Currently pregnant or lactating
  12. Currently participating in another clinical trial, or participation in another clinical trial within 30 days of enrollment
  13. Hypersensitivity to Dextran-40 or Dimethyl Sulfoxide (DMSO)
  14. Current pharmacotherapy using hydroxychloroquine or Interleukin-6 inhibitors
  15. History of CVA or MI within 180 days of study enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04398303


Contacts
Layout table for location contacts
Contact: Laura Fairbairn 403-921-5854 regulatory@aspire2cure.com

Sponsors and Collaborators
Aspire Health Science
Additional Information:
Layout table for additonal information
Responsible Party: Aspire Health Science
ClinicalTrials.gov Identifier: NCT04398303    
Other Study ID Numbers: AHS 20-03
First Posted: May 21, 2020    Key Record Dates
Last Update Posted: May 21, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aspire Health Science:
Stem cells
Pneumonia
COVID
COVID-19
Coronavirus
SARS-CoV-2
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections